TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Avecho Biotechnology Limited ( (AU:AVE) ) has provided an update.
Avecho Biotechnology Limited reported a significant increase in revenue by 79.4% to $560,069 for the half-year ended June 30, 2025, driven by research and development tax incentives. Despite this, the company experienced a 23% increase in losses, amounting to $2,675,960, due to higher expenses from ongoing operations, primarily attributed to a Phase III Clinical Trial for an oral cannabidiol capsule targeting insomnia. The company also reported a substantial net operating cash inflow of $4,532,100, bolstered by a $4,832,762 upfront licensing fee from Sandoz, which improved their working capital position.
More about Avecho Biotechnology Limited
Avecho Biotechnology Limited operates in the biotechnology industry, focusing on developing and commercializing pharmaceutical products. The company is involved in research and development, particularly in the area of oral drug delivery systems, with a market focus on improving the efficacy of pharmaceutical compounds.
Current Market Cap: A$22.21M
Find detailed analytics on AVE stock on TipRanks’ Stock Analysis page.